Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs Nerdwallet Inc — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $44.11 (market cap $7.10B), while Nerdwallet Inc trades at $9.93 (market cap $610.47M). The key difference: Ionis Pharmaceuticals Inc. Common Stock is far larger — about 11.6× Nerdwallet Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Nerdwallet Inc for 45 Days on average.
| IONS | NRDS | |
|---|---|---|
Market Cap | $7.10B | $610.47M |
Volume | 2,027,457 | 506,928 |
Sector | Health | Media |
52-Week High | $86.50 | $15.93 |
52-Week Low | $42.38 | $7.58 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $6.66B | $524.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NerdWallet (NRDS) trades at $9.77, up 1.35% with strong technical momentum and bullish moving average signals. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, turning profitable with $49M net income. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.09 expected, though Q1 and Q4 2025 results beat estimates. Analyst sentiment remains positive with 66.7% buy ratings and technical indicators showing overall bullish momentum despite some overbought RSI readings.
The outlook remains constructive given NRDS's attractive valuation multiples (P/E 10.6x, P/S 0.8x) and strong profitability metrics (18.2% ROE). Key risks include execution challenges in credit card and small-business segments, competitive pressures, and macroeconomic sensitivity. With projected 2026 revenue of $860M and net income of $65M, the stock offers growth potential though investors should monitor quarterly execution against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
